RenovoRx, Inc. (RNXT) stock
RNXTNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
$1.12+0.08 (+7.69%)
Close on Nov 18, 2026Market cap $50.55MP/E –Yield –
RenovoRx gross profit
Gross profit is revenue minus the direct cost of the goods and services sold.
RenovoRx's gross profit for the twelve months ending Jun 30, 2026 was $1.67M. For fiscal 2025 it was $796.00K, up 1751.2% from the year before.
Annual gross profit
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $796.00K | +1751.2% |
| FY2024 | Dec 31, 2024 | $43.00K | – |
Quarterly gross profit
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $766.00K | +183.7% |
| Q1 FY2026 | Mar 31, 2026 | $479.00K | +365.0% |
| Q4 FY2025 | Dec 31, 2025 | $210.00K | – |
| Q3 FY2025 | Sep 30, 2025 | $213.00K | – |
| Q2 FY2025 | Jun 30, 2025 | $270.00K | – |
| Q1 FY2025 | Mar 31, 2025 | $103.00K | – |
See a number that looks wrong?